MDG1 Stock Overview
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer.
Price History & Performance
|Historical stock prices|
|Current Share Price||€2.61|
|52 Week High||€4.59|
|52 Week Low||€1.90|
|1 Month Change||-11.22%|
|3 Month Change||-30.40%|
|1 Year Change||-32.91%|
|3 Year Change||-67.84%|
|5 Year Change||-75.90%|
|Change since IPO||-99.05%|
Recent News & Updates
We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
|MDG1||DE Biotechs||DE Market|
Return vs Industry: MDG1 underperformed the German Biotechs industry which returned -31.4% over the past year.
Return vs Market: MDG1 underperformed the German Market which returned -12.9% over the past year.
|MDG1 Average Weekly Movement||7.9%|
|Biotechs Industry Average Movement||7.9%|
|Market Average Movement||6.3%|
|10% most volatile stocks in DE Market||10.6%|
|10% least volatile stocks in DE Market||3.4%|
Stable Share Price: MDG1 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MDG1's weekly volatility has decreased from 15% to 8% over the past year.
About the Company
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies.
Medigene Fundamentals Summary
|MDG1 fundamental statistics|
Is MDG1 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDG1 income statement (TTM)|
|Cost of Revenue||€1.36m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 03, 2022
|Earnings per share (EPS)||-0.41|
|Net Profit Margin||-95.41%|
How did MDG1 perform over the long term?See historical performance and comparison
Is Medigene undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MDG1's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MDG1's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: MDG1 is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: MDG1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDG1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDG1 is good value based on its PB Ratio (1.4x) compared to the DE Biotechs industry average (1.5x).
How is Medigene forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDG1's earnings are forecast to decline over the next 3 years (-37% per year).
Earnings vs Market: MDG1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MDG1's is expected to become profitable in the next 3 years.
Revenue vs Market: MDG1's revenue is expected to decline over the next 3 years (-16.1% per year).
High Growth Revenue: MDG1's revenue is forecast to decline over the next 3 years (-16.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDG1's Return on Equity is forecast to be high in 3 years time
How has Medigene performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDG1 is currently unprofitable.
Growing Profit Margin: MDG1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDG1 is unprofitable, and losses have increased over the past 5 years at a rate of 8.8% per year.
Accelerating Growth: Unable to compare MDG1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDG1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: MDG1 has a negative Return on Equity (-22.28%), as it is currently unprofitable.
How is Medigene's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MDG1's short term assets (€24.2M) exceed its short term liabilities (€8.0M).
Long Term Liabilities: MDG1's short term assets (€24.2M) exceed its long term liabilities (€6.6M).
Debt to Equity History and Analysis
Debt Level: MDG1 is debt free.
Reducing Debt: MDG1 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDG1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MDG1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Medigene current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDG1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDG1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDG1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDG1's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MDG1 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Prof. Dr. Dolores J. Schendel has been the Chief Executive Officer and Member of Executive Management Board at MediGene AG since February 1, 2016 and May 1, 2014 respectively. Prof. Dr. has been the Chief...
CEO Compensation Analysis
Compensation vs Market: Dolores's total compensation ($USD422.10K) is about average for companies of similar size in the German market ($USD404.30K).
Compensation vs Earnings: Dolores's compensation has been consistent with company performance over the past year.
Experienced Management: MDG1's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: MDG1's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medigene AG's employee growth, exchange listings and data sources
- Name: Medigene AG
- Ticker: MDG1
- Exchange: XTRA
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €64.109m
- Shares outstanding: 24.56m
- Website: https://www.medigene.com
Number of Employees
- Medigene AG
- Lochhamer Strasse 11
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.